New Zealand Paient Spedficaiion for Paient Number 503636
Veterinary Vaccines
The present invention relates to novel vaccine compositions for parenteral administration. Described but not claimed are methods for their use and to processes for their preparation.
Bacterial and viral diseases of sheep, such as Clostridial diseases, cause considerable economic 5 damage in the agriculture industry .Vaccination is therefore a very important means of controlling these diseases
Many currently available vaccines are comprised of killed antigens, whether inactivated bacterial cells,
viral particles or cellular components, absorbed onto alkali earth metal salts (ie aluminium phosphate or aluminium hydroxide) or as water in oil emulsions For these vaccines it is recommended that naive 10 animals (ie animals which have not been previously vaccinated) are treated in a two stage dose regime consisting of an initial dose and a second booster dose several weeks later The action of the booster dose raises the antibody titre to a level that may sustain protection from a disease causing challenge organism for an extended period Animals undergoing this vaccination program are usually mustered each year for revaccination Clearly such initial two-dose administration is time consuming 15 and expensive and is therefore undesirable
The aluminium based vaccines have been found to have relatively short duration of protection while water-in-oii emulsion vaccines have a longer duration of protection but have been found to be unsuitable for use because they cause unacceptable lesions at the injection sites of the animals ('Experimental Clostridial Oil Emulsion Vaccines' Thomson RO and Batty I, Bull Off int Epiz 1967 20 67 (11-12)1569-1581, 'The immunogemcity of a multicomponent Clostridial Oil Emulsion Vaccine in sheep' Thomson et al The Veterinary Record, 26 July 1969) In 1976 Jansen et al reported the immune response of CI botulmum C and D toxoids in a water-in-oil emulsion vaccine and noted that the two-stage aluminium based vaccine was not boosted by the second dose to the same extent as the water in oil compositions (Jansen, B C, Knoetze, P C & Visser, F, Onderstepoort J Vet Res, 43(4) 25 165-174 (1976)) However, the water in oil compositions gave an undesirable granulomatous swelling resulting from subcutaneous injection of the vaccine in a large percentage of animals which is a severe disadvantage for the vaccine's commercial use
WO 91/00106 discloses multi-phase emulsions suitable for administering active substances or antigens by injection of the water in oil in water type These emulsions are produced from 30 pharmaceutical^ acceptable emulsifiers which when dissolved in an injectable oil, form a homogeneous clear phase and have inversion points approaching the temperature of human or animal bodies The oils contained in the emulsions include mineral, vegetable or animal oils, and synthetic hydrocarbons It was observed that these vaccines were well tolerated in pigs and did not cause any local reactions, abscesses or necroses However, no data were provided regarding the 35 level and duration of the immune responses
The applicants provide vaccines which are suitable for the prevention of clostridial diseases of sheep and in particular lambs, providing an effective immunity for up to a year or more following a single injection or dose Therefore, the present invention addresses the problems associated with known vaccines, providing a level of effective immune response in sheep for the period of approximately one 40 year or more following a single injection or dose of vaccine The present invention also provides
WO 99/20305 2 PCT/AU98/00865
vaccines which provide an effective immunity against each of a number of diseases for up to a year or more following a single injection or dose of a multivalent vaccine The selection of an adjuvant which enhances the antigenic response to clostridial antigens in sheep is thus a problem addressed by the invention The selection of an adjuvant which enhances the antigenic response to each of a number of micro-organisms in sheep is a particular problem addressed by the invention.
Thus according to the present invention there is provided a sheep vaccine composition compnsing:
a) an oily adjuvant acceptable for vetennary purposes comprising:
i) a white mineral oil having a molecular weight of about 250 to 300 and li) a mannitol oleate emulsifier and b) an aqueous phase comprising one or more clostridial antigens.
When used herein the term "sheep" refers to lambs as well as developing and mature sheep. The vaccines of the invention are particularly useful in the vaccination of lambs The vaccine composition is an injectable emulsion of the water in oil type and preferably has a viscosity of about 200mPas or less, more preferably about 100mPas to about 150mPas The white mineral oil is preferably between about 50% and about 70% by weight of the emulsion more preferably between about 53% and about 63% by weight of ihe emulsion. The mannitol oleate emulsifier is preferably between about 2% and about 10% by volume of the emulsion more preferably between about 3% and about 7%.
The white mineral oil has a molecular weight of about 250 to 300, preferably about 270 to 290, more preferably about 280 The oil is preferably one which is liquid at 4°C and has a viscosity lower than 100mPas at 25°C. It preferably has a density at 20°C of about 815 to 840kg/m3, more preferably about 817 to 837kg/m3 The dynamic viscosity of the oil at 25°C is preferably about 5 to 15mPas, more preferably about 6 to 13mPas. The oil preferably has a kinematic viscosity at 40°C of about 5 to 10mm2/s, more preferably about 7.5mm2/s. Preferred embodiments of the invention include the commercially available oil Marcol 52 which is supplied by ESSO
The mannitol oleate emulsifier is preferably an anhydromannitol ether octadecanoate Preferred emulsifiers have a viscosity at 25°C of about 300 to 400cP, more preferably about 340 to about 360cP, particularly preferred embodiments are those in which the emulsifier has a viscosity of about 350cP The emulsifier preferably has a specific gravity at 20°C of about 0 8 to 1 0, more preferably of about 0.95 to about 0 99, particularly suitable are those with a specific gravity at 20°C of about 0 97 Particularly preferred emulsifiers are those with a refractive index at 25°C of about 1.4 to 1 5, more preferably of about 1 47 to 1 48, particularly those with a refractive index at 25°C of about 1 4748 to 1 4758 Particularly preferred oils are the commercially available ones Montanide 80, Montanide 103 and Montanide 888 supplied by SEPPIC SA, 75 Quai D-Orsay, 75007 Paris. Montanide 103 and Montanide 888 being more preferred and Montanide 888 being most preferred It will be apparent to a person of skill in the art that the proportion of oily adjuvant to aqueous phase included in the emulsion can be adjusted to optimise vaccines including particular antigens and for use in particular animals It can also be modified to optimise vaccines for administration at a particular site
Printed from Mimosa
WO 99/20305 PCT/AU98/00865
3
The site of administration may also affect the efficacy and/or the site reactions caused by the vaccines. It will be apparent to a person of skill in the art that the site of administration can be selected so as to optimise the effects of vaccines including particular antigens and for use in particular animals. The vaccines exemplified herein were found to be efficacious regardless of site of administration, 5 however site reactions from the exemplified vaccines were more numerous when they were administered at the brisket.
Clostridial antigens suitable for use in the compositions of the present invention include Clostridium perfrmgens type A, B, C and D, Clostridium septicum, Clostridium tetani, Clostridium chauvoei, Clostridium novyi type B, Clostridium sordelli, Clostridium haemolyticum, Clostridium chauvoei and 10 Clostridium botulinum C and D. Suitable antigens include those which are useful in the treatment of diseases such as Lamb dysentery, Pulpy Kidney disease (enterotosemia), Malignant Oedema (blood poisoning), Tetanus, Blackleg disease and Black disease.
Antigens suitable for use in the present invention are any which provide a suitable immune response, eg toxoids or anacultures Suitable antigens include Clostridium perfrmgens A, B, C and D toxoids, 15 Clostridium novyi B toxoid, Clostridium chauvoei anaculture, Clostridium septicum toxoid, Clostridium tetani toxoid and Clostridium sordelli toxoid
The vaccine is preferably a multi-valent vaccine, ie. a vaccine providing protection against a number of different clostridial diseases by incorporating a number of different clostridial antigens eg the vaccine may contain any number of antigens selected from the list provided above It is particularly 20 useful to provide a multivalent vaccine, ie. one which provide adequate immune response to a number of pathogens to increase the protection provided by the vaccine It is particularly difficult to provide multivalent vaccines because it is necessary to provide a vaccine which induces an adequate antigenic response to all the micro-organisms of interest Thus the threshold antibody responses are described in compendial standards (eg Australian Therapeutic Goods order No. 30, Bntish 25 Pharmacopoeia; European Pharmacopoeia and United States Code of Federal regulation) Where compendial standards do not exist (eg for Corynebacterium pseudotuberculosis) recognised thresholds based on protection from challenge are accepted
Preferred embodiments of the invention are vaccines comprising at least two types of clostridial antigen, each one being active against any one of the following Clostridium perfnngens, Clostridium 30 novyi; Clostridium chauvoei, Clostridium septicum and Clostridium tetani Particularly preferred embodiments being vaccines comprising an antigen to all five diseases listed Particular embodiments are vaccines comprising at least two of the following types of clostridial antigen. Clostndium perfrmgens D toxoid, Clostridium novyi B toxoid, Clostridium chauvoei anaculture, Clostridium septicum toxoid and Clostridium tetani toxoid A particularly preferred embodiment being a 35 vaccine compnsing all five antigens listed The vaccine may also comprise antigens against other diseases eg Pasteureila antigens such as Pasteurella maltocida and Pasteureila haemolyticum; Corynebactenum antigens such as Corynebacterium pseudotuberculosis, Corynebacterium renale, Corynebacterium cystitis and Corynebacterium pilosum, and Haemophilus antigens such as Haemophilus somnus and
Printed from Mimosa
WO 99/20305 PCT/AU98/00865
4
Haemophilus pleuropneumonias, Mycoplasma antigens such as Mycoplasma agalactiae and Mycoplasma ovipneumoniae.
Further preferred embodiments of the invention are those which comprise Corynebactenum antigens such as Corynebactenum pseudotuberculosis, Corynebacterium renale, Corynebactenum cystitis and 5 Corynebacterium pilosum A particularly preferred embodiment of the invention compnses antigens of Clostndium periringens D toxoid; Clostndium novyi B toxoid, Clostridium chauvoei anaculture; Clostridium septicum toxoid, Clostridium tetani toxoid and Corynebacterium pseudotuberculosis
The invention particularly relates to vaccines comprising one or more Clostridial antigens in 10 combination with one or more non-Clostndial antigens Co-adjuvants may optionally be included in the vaccines of the present invention. The antigens may be in the form of toxoids or cell antigens but if cell antigens are used a co-adjuvant may be required. Such co-adjuvants may suitably include a saponin (eg quil A) or cytokines such as Interleukin-1, 2, and 4 or muramyl dipeptide. Further emulsifiers such as dioctyl decyl ammonium bromide (DDA) may 15 also be included in the vaccines if desired The vaccine composition of the present invention may contain one or more antigens and one or more emulsifiers and/or one or more co-adjuvants Supplements such as selenium which is important for growth and reproductive processes may also be included in the vaccine
Vaccines according to the present invention may be prepared by dissolving antigens in a suitable 20 aqueous medium such as normal saline, stirring the resultant mixture and adding it to a suitable oil phase. The mixture is then stirred (eg at 200 to 600rpm) and/or homogenised (eg at 500 to 4500psi) to the desired viscosity (<200mPas) and conductivity <0 5 millisiemens at 20°C. Preservatives such as thiornersal may optionally be included in the aqueous mixture prior to adding the antigens. This process is preferably carried out at about 20°C to about 25°C.
Surprisingly it has been found that the vaccines of the invention can provide a sustained and elevated immune response when administered to the target animals, sheep, in a single dose They are preferably capable of inducing a response which can be measured, eg., by ELISA or SN neutralisation titres, for a period of at least 12 months The vaccine compositions of the present invention are stable and may be stored for several months or even years without loss of antigenic potency. The vaccines 30 are capable of overcoming maternal antibody The present invention will now be exemplified with reference to the following Examples by way of illustration only
Example 1
Preparation and efficacy of a single dose clostridial plus Corynebactenum pseudotuberculosis 6-in-1 35 vaccine for use in sheep
Vaccine compositions were prepared according to Table I below. The compositions were initially prepared by mixing Clostridial and Corynebacterium pseudotuberculosis antigens with normal saline and thiornersal at room temperature to prepare the aqueous phase of the vaccines. The pH of the aqueous phase being between pH7 and pH7 5.
Printed from Mimosa
WO 99/20305 PCT/AU98/00865
For composition 1 the aqueous phase was added to a mixture of Marcol 52 and Montanide 888 (ratio 10 7 to 1 pre-equilibrated to room temperature). This mixture was then homogenised to create a water-in-oil emulsion (viscosity <200mPas) The dose volume of Composition 1 was 1mL.
Composition 2 was prepared in a similar manner except that an aluminium based adjuvant, Tasgel 5 was added instead of the Marcol 52/Montanide 888 mixture The aqueous phase/Tasgel mixture was stirred at 100 to 600rpm at room temperature for 15 minutes and the pH adjusted with HCI to pH 6 5±0.3. The dose volume of Composition 2 was 2mL
Table I Vaccine Compositions
Component
Composition (amount % v/v)
1
2
CI perfrmgens D toxoid
.2
2 60
CI novyi B toxoid
94
297
CI chauvoei anaculture
44
22
CI septicum toxoid
1 4
0.7
CI tetani toxoid
9
45
C pseudotuberculosis toxoid
0.84
042
MilliQ
13 9
55 6
Thiornersal
1
Marcol 52/ISA 888
58 5
Tasgel
The efficacy of the vaccines was tested using a group of thirty approximately four year old pregnant
ewes (first cross Border-Leicester) identified by ear tags The ewes were vaccinated subcutaneously with the vaccines descnbed above approximately two to three weeks prior to the onset of lambing Twenty lambs born to the previously vaccinated ewes were vaccinated by subcutaneous injection of the vaccine compositions The vaccine regimes are shown below in Table II:
Table II Vaccine regimes for ewes and lambs
Group
Vaccine/adiuvant
Lambs or Ewes vaccinated
No of Animals vaccinated
Dose vol (mL)
1
6 in 1/Tasgel
Ewes
2
2
6 in I/M52-M888
Ewes
4
Non-vaccinate (control)
Lambs
4
-
6 in 1/Tasgel
Lambs
2
6
Non-vaccinate(control)
Lambs
11
-
7
6 in 1/M52-M888
Lambs
1
Lambs were at least eight weeks old when vaccinated. Only Group 5 received a second vaccination at
Week 4, these animals were vaccinated with 6 in 1 vaccine comprising Tasgel as adjuvant Serum samples were collected from blood centrifuged for 15 minutes at 3000rpm and at room temperature. The following assays were performed on serum samples.
CI perfrmgens D ELISA was performed on individual serum samples using purified rabbit anti-CI 20 perfrmgens epsilon toxin diluted in carbonate buffer pH9 6 in a 96 well microtitre plate. This was incubated at 37°C for 2h before purified CI perfringens toxin diluted in phosphate buffered saline/Tween 20 (01%w/v) was added and the plate incubated at 37°C for 1h Dilutions of sheep sera (and positive and negative sera) were added to the wells and the plate incubated for 1h at 37°C The plates were then washed with PBS/Tween and a dilution of rabbit anti-sheep IgG horseradish 25 peroxidase conjugate (Biorad) in PBS/Tween added The plate was incubated at 37°C for a further hour and then washed with PBS/Tween Activated substrate (2,2-azino-di-3-
Printed from Mimosa
WO 99/20305 PCT/AU98/00865
6
ethyIbenzthiazoIinosuifonate) dissolved in citrate phosphate buffer pH4 6 at 1mg/mL and activated by addition of 0./3% hydrogen peroxide was added to the plate. Absorbance at 405nm was read after 30 to 60 minutes using a Titertek Multiscan reader.
The procedure was repeated using purified CI. tetani toxoid in the CI tetani ELISA on individual serum 5 samples.
Mice serum neutralisation titres of pooled group sera for CI. novyi, CI. tetani,, CI. septicum and CI. perfringens D were earned out according to the Therapeutic Goods Order No. 30 (Australian Government Publishing Services, 1987).
Corynebacterium pseudotuberculosis (C. pseudotuberculosis) serum neutralisation titres were 10 determined for individuals and pooled sera samples based on observations by Muckel & Giles, Am. J Vet Res. 44, 1149-1153, 1983 in order to measure a response to the Corynebacterium pseudotuberculosis antigens.
The pregnant ewes were monitored on Day 0, Day 1 and Day 14 (Week 2) following vaccination. No ewes appeared distressed Rectal temperatures were recorded on those days and a summary is 15 shown in Table III.
Table III Rectal temperatures of pregnant ewes prior to and following vaccination
Group vaccine/adiuvant
Mean rectal temperature (°C)
Day
0
1
14
1 6 in 1/Tasgel
39 7±0.3
400+0 5
39 6±0 3
2 6 in 1/M52-M888
39 7±02
4Q.2±0 5
39 5±0.3
Site reactions were recorded for the lambs and are shown below in Table IV. They were found to be negligible for each type of vaccination
Group
Week 4
Week 8
Week 12
Week 20
Week 26
Week 30
4
Non vaccinates
0 (0/3)
0 (0/5)
0 (0/5)
0 (0/5)
0 (0/5)
0 (0/5)
0 (0/5)
6
Non vaccinates
0 (0/6)
7
1 8(1/13)
0 5(1/15)
0 6(1/14)
0(0/15)
0(0/5)
0(0/8)
The figures presented in brackets represent the number of lambs with site reactions/number of lambs per group.
Selected groups were revaccinated at Week 26 and no site reactions were reported at Week 30 The weights of lambs were recorded and are shown below in Table V. No significant difference in weights or weight gain based on 95% confidence interval of the mean for each group at each time point and 25 between non-vaccinates and vaccinates was found (p >0.05).
Table V Weights of lambs (kg)
Average weight at week
Group
Markmq
4
8
12
Average weight gain over 12 weeks
4
21 6±40
31 6±4 2
0±5 0
42 3+5 5
19 8±21
22 1±2 5
31 1±34
33.5±3.7
38.2±3 9
16.1 ±1.6
6
19 6±5 2
27 9±5.3
.8±5.9
351+6 2
5±2.5
7
21.3±3 5
8±3 8
32 6±3 9
37 4+3 7
16 1±3 2
Printed from Mimosa
WO 99/20305 PCT/AU98/00865
CI. perfringens D ELISA Titres
Cl. perfringens D ELISA titres were determined for both ewes and lambs to evaluate vaccine efficacy Tables VI and VII record CI. perfringens D ELISA titres for pregnant ewes and lambs (respectively) Groups 4 and 5 were given a booster vaccination of 6 in 1 vaccine with Tasgel adjuvant at Week 26. 5 Tables VIII and IX show SN's for pregnant ewes and lambs (respectively)
Table VI CI. perfringens D ELISA (
U/mL) of ewes
Group adiuvant
WeekO
Week 17
Week 37
1
6 in 1 Tasgel 1 x2mLdose
1 4
43
87
2
6 in 1 M52-M8881x1mLdose
26
244
23.2
The results displayed are the GMT of individual titres for that group
Table VII CI. perfringens D ELISA Titres in lambs
Mean ELISA Titres (U/mL)
Group
0
4
8
12
26
O CO
4
1 1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1 3
6
32
<1
<1
<1
<1
<1
7
22
21
3.4
39
44
28
3.5
Table VIIISN Titres in pregnant ewes
Group adjuvant
17 weeks after vaccination
1
6 in 1 Tasgel 1x2mL dose
CI. perf D
5-11
CI tet
8-10
CI novyi B
6-8
CI sept
<2
2
6 in 1 M52-M888 1x1 mL dose
CI perf D
13.2-16 5
CI tet
>12
CI novyi B
3-5
CI sept
>10
Table IX SN Results for lambs
Group
Vaccine
WeekO
[Week 8
6 in 1 Tasgel 2x2mL dose
Cl perf D
1.7-2 5
CI perf D
<3 65
CI tet
2 5-3.8
CI tet
<2
CI novyi B
2 3-3 5
CI novyi B
1 5-2 3
CI sept
<2
CI sept
<2
C pseudot
21
C pseudot
0.2
7
6 in 1 M52-M888 1x1 mL dose
CI. perf D
<1 1
CI perf D
<3.6
CI. tet
17-2 5
CI tet
2.5-3.8
CI novyi B
1 5-2 3
Cl novyi B
2 3-3 5
CI sept
<2
CI sept
<2
C pseudot
12
C pseudot
01
Group
Vaccine
Week 26
Week 30
6 in 1 Tasgel 2x2mL dose
CI perf D
<1 1
Cl perf D
<4
CI tet
<1 1
Cl tet
>41
CI novyi B
<1 0
Cl novyi B
71-107
CI sept
<20
Cl sept
<2 0
C pseudot
08
7
6 in 1 M52-M888 1x1 mL dose
CI. perf D
1 1-17
CI tet
<1 1
CI novyi B
<10
CI sept
<2 0
C pseudot
1 1
Printed from Mimosa
WO 99/20305 PCT/AU98/00865
8
Vaccination of lambs in Group 7 with the single dose M52-M888 adjuvanted vaccine (the same vaccines as their mothers were vaccinated with) indicated that maternal antibody could be overcome by providing a response to vaccination, when compared to the standard (Group 5). Companng non-vaccinates with vaccinates (Groups 4 and 5 or groups 6 and 7) maternal antibody appeared to decline 5 to a level below the sensitivity of the ELISA by Week 4 following marking The 95% confidence intervals of the mean for each group indicate that from Week 8 onwards only Group 7 has a statistically significantly higher titre than all other groups (p <0 05) Thus, based on these ELISA results and similar analysis for other Clostridial and bacterial components, the capacity of a single dose of the M52-M888 adjuvanted vaccine to generate responses is at least as good as the two dose 10 vaccine Furthermore the M52-M888 adjuvanted vaccine was administered in a single dose.
Example 2
Preparation and efficacy of a single dose clostridial 5-in-1 vaccine for use in sheep
Vaccine compositions used in this example were prepared in a similar manner to the compositions described above in Example 1 (see Table I) except that the C. pseudotuberculosis antigen was 15 omitted Selenium (1mg per dose) was added to the aqueous phase prior to mixing with either Marcol 52/Montanide 888 or Tasgel
Fine wool Merryville Merino ewes and lambs, identified by numbered ear tags, were vaccinated subcutaneously in the left side of the neck in accordance with the regime set out below in Table X. They were vaccinated on the right side of the neck when a second and/or booster dose was required 20 All these lambs were derived from Merino ewes that had been previously vaccinated with 5 in 1 Tasgel vaccine 1 month prior to lambing
Table X Vaccine groups
Group
Vaccine Antigen/ Adiuvant
No. of Lambs
Dose Volume (mL)
1
Non-vaccinates
-
2
in 1/Tasgel
18
2
3
in 1+Se/Tasgel
18
2
4
in 1/M52-M888
18
1
in 1Se/M52-M888
18
1
Lambs were vaccinated when four to eight weeks old. Groups 2 and 3 were vaccinated with a second dose of 5 in 1 Tasgel vaccine at week 4. Groups 2,3,4 and 5 received a booster vaccination with the
respective vaccinates for the group at week 51
Serum samples were collected from blood centnfuged at 3000rpm, 15min at room temperature The assays described above in Example 1 were performed on the serum samples.
Site reactions following vaccination were not found in any of the Merino lambs No adverse affects on the lambs' general well being as a result of vaccination were observed
Cl. perfringens D and Cl. tetani ELISA Titres
The response of the lambs to vaccination was assessed by measurement of Cl. perfrmgens D and Cl tetani antibody responses using specific ELISAs. Cl Perfringens D results are presented below in Table XI and Cl tetani results are presented in Table XII
Printed from Mimosa
WO 99/20305 PCT/AU98/00865
9
Table XI CL perfringens D ELISA Titre in Lambs (U/mL)
Group
Vaccine Antigens/Adjuvant
Vaccination (week)
Cl perfringens ELISA Titre (U/mL)
WEEK
0
4
8
12
19
26
51
55
1
Non-vaccinate
1 6
<1
<1
<1
<1
<1
<1
<1
2
in 1 Tasgel
0,4
22
<1
<1
29
<1
<l
<1
14
3
in 1 +Se/Tasgel
0,4
36
<1
<1
1
<1
<l
<1
24
4
in 1 M52/M888
0
27
.1
11 5
17
80
13.6
126
156
in 1 +SeM52/M888
0
<1
1 3
48
92
8
16.8
Table XII Cl. tetani ELISA Titre in Lambs (U/mL)
Group
Vaccine Antigens/Adjuvant
Vaccination (week)
Cl tetani ELISA Titre (U/mL)
WEEK
0
4
8
12
19
26
51
55
1
Non-Vaccinate
1 9
<1
<1
<1
<1
<l
<1
<1
2
in 1/Tasgel
0,4
<1
<1
<1
<1
<1
<1
<1
19
3
in 1+Se/Tasqel
0,4
<1
<1
<1
<1
<1
<1
<1
16
4
in 1/M52-M888
0
<1
<1
45
104
23
34
1 3
104
in 1+Se/M52-M888
0
1.4
<1
52
56
1
24
1 5
.4
Both Cl. perfringens D and Cl. tetani ELISA titres in lambs were detected over 51 weeks following a single dose vaccination with the M52-M888 adjuvanted vaccine formulation. In comparison, ELISA 5 titres were not detectable following two doses of the 5 in 1 gel vaccine This may be due to the levels of maternal antibody present in the lambs In Group 4 where maternal antibody was detected at marking (week 0), the M52-M888 adjuvanted vaccine formulation overcame maternal antibody to produce a strong response
The M52-M888 adjuvanted vaccines showed higher efficacy than the 5 in 1 Tasgel adjuvanted 10 vaccine formulations. Furthermore the M52-M888 adjuvanted vaccine formulation (Group 4 J was used in a single dose regime compared to a two dose regime for the gel formulations (Groups 2 and 3) The addition of selenium did not offer any immunological advantage, although it is known to act as an immune stimulant. It is primarily added as a mineral supplement to these vaccines SN Titres in Lambs
SN titres for Cl perfringens D, Cl tetani, Cl septicum and Cl novyi B were determined for selected pooled group sera samples from Groups 1 to 5 At Week 12, only lambs vaccinated with the 5 in 1 M52/M888 adjuvanted vaccine formulation (Group 4) gave detectable SN titres for the components Cl. perfringens D, Cl. tetani, Cl. septicum and Cl novyi B. By Week 19 SN titres for Cl. tetani and Cl novyi B remained detectable for this formulation Results are presented below in Table )XIII. Pooled 20 group sera from lambs vaccinated with formulations containing selenium were only assayed at Week 12 for Cl perfringens D and Cl tetani Results were similar to that found in lambs vaccinated with formulations without selenium.
Printed from Mimosa
Table XIII Serum neutralisation ti
Group
Vaccine
(Antigen/Adiuvant)
Vaccination (week)
Antigen
Week 0
Week 4
Week 8
Week 12
1
Non-vaccinates
Cl. perfringens D
<36
<14
Cl. tetani
<2.0
<2 2
Cl septicum
NA
NT
NT
NT
Cl novyi B
<1.5
NT
2
in 1 Tasgel
0,4
Cl perfnngens D
<3.6
<3 6
<3.6
<14
Cl. tetani
<2 0
<2.0
<2.0
<2 2
Cl septicum
<2 2
<2.2
<180
<1 8
Cl novyi B
1.5-2 3
<15
2 3-3 5
<1 6
3
in 1 + Se Tasgel
0,4
Cl perfnngens D
<14
Cl tetani
<2 2
Cl septicum
NT
NT
NT
NT
Cl novyi B
NT
4
in 1 M52-M888
0
Cl perfnngens D
<3 6
3 6-4 5
9 0-13.6
4 6-6 9
Cl. tetani
<2.0
2.5-3 8
8.6
6.2-9.3
Cl septicum
<2.2
<2.2
2.3-3.4
2 3-3 4
Cl novyi B
<15
3 5-5 3
8 0-12 0
3-7 9
in 1 + Se M52-M888
0
Cl perfringens D
3
Cl tetani
2 8-41
Cl septicum
NT
NT
NT
NT
Cl novyi B
NT
Group
Vaccine
(Antigen/Adiuvant)
Vaccination (week)
Antigen
Week 19
Week 51
Week 55
1
Non-vaccinates
Cl perfnngens D
<3.0
<1 1
Cl. tetani
<2 2
<1 2
Cl septicum
<1 8
<2
NT
Cl novyi B
<14
<1
2
in 1 Tasgel
0,4
Cl perfringens D
<3 0
<1 1
<1 1
Cl. tetani
<2.2
<1 2
NA
Cl septicum
<1 8
<2
<2
Cl novyi B
<14
<1
3 5-5 3
3
in 1 +Se Tasgel
0,4
Cl perfringens D
Cl tetani
Cl septicum
NT
NT
NT
Cl novyi B
4
in 1 M52-M888
0
Cl perfnngens D
<3 0
<1 1
>8.8
Cl tetani
41-6 2
<12
1 8-2 8
Cl. septicum
<1 8
<2
8 6-129
Cl novyi B
21-3 2
<1
>8
in 1 + Se M52-M888
0
Cl perfringens D
Cl tetani
Cl septicum
NT
NT
NT
Cl novyi B
res in lambs
Rabbit Potency
The vaccines were assessed in the standard rabbit potency test (Therapeutic Goods Order No. 30 Australian Government Publishing 1987) A summary 5 of results is presented in Table XIV. The vaccine formulation of 5 in 1 M52-M888 adjuvanted vaccine formulation (Group 4) passed potency in all fractions, following a single dose vaccination. This result
Printed from Mimosa